A Study of XW003 Injection in Chinese Adolescents With Obesity

What Was Tested

The trial (phase 1) is built around Ecnoglutide.

It had four arms (groups): one (experimental), one (experimental), one (experimental) and placebo (placebo comparator).

Once weekly.

Once weekly.

Once weekly.

The registry classes the interventions as drug.

More on the Plan

In this study, eligible participants will be randomized into one of the three cohorts in a 3:1 ratio to receive either once-weekly subcutaneous XW003 injection or placebo, for up to 20 weeks.

Who Took Part

Enrollment: 48 actual participants took part.

It was open to people of any sex aged from 12 years up to 18 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: At the time of screening, BMI meets the obesity criteria specified in WS/T586-2018 'screening for overweight and obesity among school-aged children and adolescents', and weight ≥55 kg;.

The full record lists 2 inclusion and 5 exclusion criteria; among the exclusions: pre-adolescent participants (tanner phase i);; diagnosis with any type of diabetes;; history of acute or chronic pancreatitis, history of gallbladder disease or pancreatic injury.

How the Study Was Run

It was run as a randomized, parallel-group and double-blind study.

Because people in this Ecnoglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The Ecnoglutide group and the comparison group ran side by side rather than switching.

Neither the participants nor the staff measuring them knew who was on Ecnoglutide, so expectations could not easily colour the readings.

Those kept unaware of assignments: participant and investigator.

It started in 2025-08-25 with completion listed for 2026-04-18.

It ran at 1 site in China.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Number and severity of adverse events (time frame: week 20).

It also tracked 2 secondary outcomes, for example Plasma concentrations of XW003 and Change of body weight from baseline.

What This Means in Plain Language

Put simply, this is a phase 1, randomized trial of Ecnoglutide in 48 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Ecnoglutide compound page, all human trials.